European Journal of Dermatology
MENUA comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience Volume 27, numéro 5, September-October 2017
Auteurs
2 Unit of Biostatistics,
Epidemiology and Public Health, Department of Cardiac,
Thoracic and Vascular Sciences University of Padua Via Loredan,
18, 35131 Padova,
Italy
Epidemiology and Public Health, Department of Cardiac,
Thoracic and Vascular Sciences University of Padua Via Loredan,
18, 35131 Padova,
Italy
* Reprints
- Mots-clés : BRAF inhibitor, cutaneous side effect, MEK inhibitor, melanoma
- DOI : 10.1684/ejd.2017.3069
- Page(s) : 482-6
- Année de parution : 2017
Melanoma is one of the most fatal cancers and is responsible for 75% of deaths from all skin cancers [1]. In the last decades, its incidence has been increasing worldwide [1]. Patients with advanced melanoma have a poor prognosis with a median survival time of 6-10 months [2]. Prior to the development of new targeted therapies, the only effective treatment for metastatic melanoma was surgery. Radiotherapy and chemotherapy (dacarbazine and other chemotherapeutic agents) did not improve the overall [...]